Voyxact: how long were the pivotal tox studies?

“A 26-week IV study (25 to 100 mg/kg biweekly) showed no adverse effects at the highest dose of 100 mg/kg/dose.”

“A 26-week IV study (25 to 100 mg/kg biweekly) showed no adverse effects at the highest dose of 100 mg/kg/dose. A 26-week study with SC dosing (25 to 100.5 mg/kg biweekly) demonstrated a similar safety profile”

“A 26-week study with SC dosing (25 to 100.5 mg/kg biweekly) demonstrated a similar safety profile and with ~70% bioavailability compared to the IV route of administration.”